Prof. Dr. Martin Früh
Stv. Chefarzt
Leitung Fachbereich Onkologie
Medizinische Onkologie und Hämatologie · Dept. I
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Stahel R, Caspar C, Eckhardt K, Schmid R, Aebersold D, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L, Mordasini C, Zippelius A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 2015; 16:1651-8.
02.11.2015Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
02.11.2015Lancet Oncol 2015; 16:1651-8
Stahel Rolf A, Caspar Clemens B, Eckhardt Katrin, Schmid Ralph A, Aebersold Daniel M, Gautschi Oliver, Nagel Wolfgang, Töpfer Michael, Krayenbuehl Jerome, Ribi Karin, Ciernik Llja F, Mordasini Carlo, Zippelius Alfred, Riesterer Oliver, Xyrafas Alexandros, Opitz Isabelle, Beyeler Michael, Ochsenbein Adrian, Früh Martin, Cathomas Richard, Nackaerts Kristiaan, Peters Solange, Mamot Christoph, Weder Walter
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Gautschi O, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Huret B, Curioni-Fontecedro A, Milia J, Cabarrou B, Bluthgen M, Besse B, Smit E, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol 2015; 10:1451-7.
01.10.2015Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
01.10.2015J Thorac Oncol 2015; 10:1451-7
Gautschi Oliver, Kerjouan Mallorie, Michels Sebastian, Pall Georg, Rothschild Sacha, Schmid-Bindert Gerald, Scheffler Matthias, Veillon Rémi, Wannesson Luciano, Diebold Joachim, Zalcman Gérard, Filleron Thomas, Huret Benjamin, Curioni-Fontecedro Alessandra, Milia Julie, Cabarrou Bastien, Bluthgen Marie-Virginia, Besse Benjamin, Smit Egbert F, Wolf Juergen, Peters Solange, Früh Martin, Koeberle Dieter, Oulkhouir Youssouf, Schuler Martin, Mazières Julien
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Pless M, Bijelovic M, Ochsenbein A, Meier U, Mamot C, Rauch D, Gautschi O, Betticher D, Mirimanoff R, Peters S, Roth A, Zippelius A, Stupp R, Ris H, Stahel R, Weder W, Thierstein S, Gerard M, Xyrafas A, Früh M, Cathomas R. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386:1049-56.
11.08.2015Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
11.08.2015Lancet 2015; 386:1049-56
Pless Miklos, Bijelovic Milorad, Ochsenbein Adrian, Meier Urs R, Mamot Christoph, Rauch Daniel, Gautschi Oliver, Betticher Daniel C, Mirimanoff René-Olivier, Peters Solange, Roth Arnaud, Zippelius Alfred, Stupp Roger, Ris Hans-Beat, Stahel Rolf A, Weder Walter, Thierstein Sandra, Gerard Marie-Aline, Xyrafas Alexandros, Früh Martin, Cathomas Richard
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.
05.03.2015Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
05.03.2015Clin Lung Cancer 2015; 16:358-65
Gautschi Oliver, Savic Spasenija, Jaggi Rolf, Leibundgut Elisabeth Oppliger, Largiadèr Carlo, Brutsche Martin, Pilop Christiane, Stalder Lukas, Pless Miklos, Ochsenbein Adrian F, Bubendorf Lukas, Feilchenfeldt Jonas, Rauch Daniel, Mach Nicholas, Rothschild Sacha I, Li Qiyu, Stahel Rolf A, Zippelius Alfred, Cathomas Richard, Früh Martin, Betticher Daniel C, Peters Solange, Swiss Group for Clinical Cancer Research
Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC)
Putora P, ess s, Panje C, Hundsberger T, van Leyen K, Plasswilm L, Früh M. Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC). Clin Exp Metastasis 2015; 32:143-9.
28.01.2015Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC)
28.01.2015Clin Exp Metastasis 2015; 32:143-9
Putora Paul Martin, ess silvia, Panje Cédric, Hundsberger Thomas, van Leyen Karin, Plasswilm Ludwig, Früh Martin
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
Koeberle D, Kollar A, Saletti P, Roth A, Früh M, Kueng M, Popescu R, Schacher S, Hess V, Moosmann P, Anchisi S, Betticher D, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Herrmann R. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol 2015; 26:709-14.
20.01.2015Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
20.01.2015Ann Oncol 2015; 26:709-14
Koeberle D, Kollar A, Saletti P, Roth A, Früh Martin, Kueng M, Popescu R A, Schacher S, Hess V, Moosmann P, Anchisi S, Betticher D C, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Herrmann R
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
Sebastian M, Gnad-Vogt U, Kallen K, Heidenreich R, Fotin-Mleczek M, Scheel B, Koch S, Rippin G, Wehler T, Hilbe W, Cathomas R, Früh M, Weiss C, Papachristofilou A, Zippelius A. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC cancer 2014; 14:748.
06.10.2014Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
06.10.2014BMC cancer 2014; 14:748
Sebastian Martin, Gnad-Vogt Ulrike, Kallen Karl-Josef, Heidenreich Regina, Fotin-Mleczek Mariola, Scheel Birgit, Koch Sven D, Rippin Gerd, Wehler Thomas, Hilbe Wolfgang, Cathomas Richard, Früh Martin, Weiss Christian, Papachristofilou Alexandros, Zippelius Alfred
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
Jörger M, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D, Stahel R, Droege C, Früh M, Baty F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 2014; 85:306-13.
29.05.2014Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
29.05.2014Lung Cancer 2014; 85:306-13
Jörger Markus, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D C, Stahel R A, Droege C, Früh Martin, Baty Florent, Brutsche Martin
Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis
Diem S, Ess S, Cerny T, Früh M, Hitz F. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. Eur J Intern Med 2014; 25:577-82.
28.05.2014Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis
28.05.2014Eur J Intern Med 2014; 25:577-82
Diem Stefan, Ess S, Cerny Thomas, Früh Martin, Hitz Felicitas
Strategy on Patients with EGFR Mutation
Früh M. Strategy on Patients with EGFR Mutation. In: New Therapeutic Strategies in Lung Cancers. Heidelberg: Springer, 2014. ISBN 978-3-319-06061-3. S. 133-145.
01.01.2014Strategy on Patients with EGFR Mutation
01.01.2014Springer, ISBN 978-3-319-06061-3
Früh Martin
Advances in Radiotherapy for Locally Advanced NSCLC
Früh M. Advances in Radiotherapy for Locally Advanced NSCLC. In: New Therapeutic Strategies in Lung Cancers. Heidelberg: Springer, 2014. ISBN 978-3-319-06061-3. S. 69-94.
01.01.2014Advances in Radiotherapy for Locally Advanced NSCLC
01.01.2014Springer, ISBN 978-3-319-06061-3
Früh Martin
Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib
Leitner C, von Moos R, Früh M, Mark M, Cathomas R. Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib. Cancer Treatment Communications 2014; 2:4-7.
01.01.2014Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib
01.01.2014Cancer Treatment Communications 2014; 2:4-7
Leitner C, von Moos Roger, Früh Martin, Mark M, Cathomas R
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Baty F, Brutsche M, Pless M, Zappa F, Crowe S, Bubendorf L, Gautschi O, Rauch D, Cathomas R, Dröge C, Betticher D, Früh M, Rothschild S, Swiss Group for Clinical Cancer Research. EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PloS one 2013; 8:e72966.
10.09.2013EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
10.09.2013PloS one 2013; 8:e72966
Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Crowe Susanne, Bubendorf Lukas, Gautschi Oliver, Rauch Daniel, Cathomas Richard, Dröge Cornelia, Betticher Daniel, Früh Martin, Rothschild Sacha, Swiss Group for Clinical Cancer Research
Management of elderly patients with advanced non-small cell lung cancer: a single-center experience
Früh M, Besrour H, Gillessen Sommer S, Jörger M, Hitz F, Savidan A, Cerny T, Ess S. Management of elderly patients with advanced non-small cell lung cancer: a single-center experience. Chemotherapy 2013; 59:42-50.
02.07.2013Management of elderly patients with advanced non-small cell lung cancer: a single-center experience
02.07.2013Chemotherapy 2013; 59:42-50
Früh Martin, Besrour H, Gillessen Sommer Silke, Jörger Markus, Hitz Felicitas, Savidan A, Cerny Thomas, Ess S
Tobacco-related cancer mortality: projections for different geographical regions in Switzerland
Jürgens V, ess s, Phuleria H, Früh M, Schwenkglenks M, Frick H, Cerny T, Vounatsou P. Tobacco-related cancer mortality: projections for different geographical regions in Switzerland. Swiss Med Wkly 2013; 143:w13771.
25.06.2013Tobacco-related cancer mortality: projections for different geographical regions in Switzerland
25.06.2013Swiss Med Wkly 2013; 143:w13771
Jürgens Verena, ess silvia, Phuleria Harish C, Früh Martin, Schwenkglenks Matthias, Frick Harald, Cerny Thomas, Vounatsou Penelope
Thymoma with molecularly verified "conversion" to T lymphoblastic leukemia/lymphoma over 9 years
Ertel V, Früh M, Guenther A, Cerny T, Fretz C, Cogliatti S. Thymoma with molecularly verified "conversion" to T lymphoblastic leukemia/lymphoma over 9 years. Leuk Lymphoma 2013; 54:2765-8.
21.06.2013Thymoma with molecularly verified "conversion" to T lymphoblastic leukemia/lymphoma over 9 years
21.06.2013Leuk Lymphoma 2013; 54:2765-8
Ertel Vera, Früh Martin, Guenther Alexander, Cerny Thomas, Fretz Christian, Cogliatti Sergio
EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report
Diem S, Früh M, Rodriguez R, Liechti P, Rothermundt C. EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report. Case Rep Oncol 2013; 6:316-9.
13.06.2013EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report
13.06.2013Case Rep Oncol 2013; 6:316-9
Diem Stefan, Früh Martin, Rodriguez Regulo, Liechti Peter, Rothermundt Christian
Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?
Schwitter M, Früh M, Schneider T, Kluckert J, Rodriguez R, Brutsche M. Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?. Oncology 2013; 2013:263-268.
14.05.2013Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?
14.05.2013Oncology 2013; 2013:263-268
Schwitter Michael, Früh Martin, Schneider Tino, Kluckert Jörg-Thomas, Rodriguez Regulo, Brutsche Martin
Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?
Schwitter M, Rodriguez R, Schneider T, Kluckert T, Brutsche M, Früh M. Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?. Case Rep Oncol 2013; 6:263-8.
14.05.2013Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?
14.05.2013Case Rep Oncol 2013; 6:263-8
Schwitter Michael, Rodriguez Regulo, Schneider Tino, Kluckert Thomas, Brutsche Martin, Früh Martin
FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma
Putora P, Früh M, Müller J. FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. Respirology 2013; 18:734-5.
01.05.2013FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma
01.05.2013Respirology 2013; 18:734-5
Putora Paul Martin, Früh Martin, Müller Joachim